Compare HFBL & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HFBL | NXTC |
|---|---|---|
| Founded | 1924 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.6M | 44.6M |
| IPO Year | 2010 | 2019 |
| Metric | HFBL | NXTC |
|---|---|---|
| Price | $17.56 | $13.52 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $23.00 |
| AVG Volume (30 Days) | 2.5K | ★ 27.3K |
| Earning Date | 04-29-2026 | 06-08-2026 |
| Dividend Yield | ★ 2.90% | N/A |
| EPS Growth | ★ 7.69 | N/A |
| EPS | ★ 1.07 | N/A |
| Revenue | $1,303,000.00 | ★ $22,378,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $16.42 | ★ N/A |
| Revenue Growth | ★ 17.49 | N/A |
| 52 Week Low | $12.32 | $0.23 |
| 52 Week High | $20.00 | $15.74 |
| Indicator | HFBL | NXTC |
|---|---|---|
| Relative Strength Index (RSI) | 41.42 | 52.39 |
| Support Level | $12.87 | $10.73 |
| Resistance Level | $18.20 | $13.47 |
| Average True Range (ATR) | 0.19 | 1.10 |
| MACD | -0.21 | 0.05 |
| Stochastic Oscillator | 5.39 | 64.68 |
Home Federal Bancorp Inc of louisiana operates as a bank holding company. It is a federally chartered stock savings bank, which provides financial services to individuals, corporate entities, and other organizations. Its core activities consist of attracting deposits from the general public and using those funds to originate loans to the residential, commercial and multi-family segments. The company also invests securities held-to-maturity and securities available for sale.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.